## AMENDMENTS TO THE SPECIFICATION

**Page 1, line 1,** please rewrite the title as follows:

~~Therapeutic Application of Chimeric and Radiolabeled~~ Anti-CD20 Antibodies ~~to Human B Lymphocyte Restricted Differentiation Antigen for Treatment of B Cell Lymphoma~~

**Page 1, line 18,** replace the paragraph setting forth the priority claim:

This is a continuation of U.S. application serial no. 08/475,813, filed June 7, 1995, now U.S. Patent No. 6,682,734; which is a divisional of U.S. application serial no. 08/149,099, filed November 3, 1993, now U.S. Patent No. 5,736,137; which is a continuation-in-part of ~~United States.~~ U.S. application serial no. 07/978,891, filed November 13, 1992, ~~pending~~ now abandoned. This patent document is related to ~~United States.~~ U.S. application serial no. 07/977,691, filed November 13, 1992, now abandoned, entitled "IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE FOR ENHANCEMENT OF EXPRESSION OF CO-LINKED GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS COMPRISING SAME," ~~having U.S. Serial No. 07/977,691 (pending; filed November 13, 1992);~~ and U.S. ~~United States.~~ U.S. application serial no. 08/147,696, filed November 3, 1993, now U.S. Patent No. 5,648,267, entitled "IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS COMPRISING SAME." ~~(U.S. Serial No. ___ filed simultaneously herewith)~~ The related patent documents are incorporated herein by reference.

**Page 16, lines 17-25,** replace the current paragraph with the following:

With reference to the use of radiolabeled anti-CD20 antibodies, a preference is that the antibody is non-chimeric; this preference is ~~predicted~~ predicated upon the significantly longer circulating half-life of chimeric antibodies vis-a-vis murine antibodies (*ie*, with a longer

circulating half-life, the radionuclide is present in the patient for extended periods). However, radiolabeled chimeric antibodies can be beneficially utilized with lower ~~milli-Curries~~ millicurie ("mCi") dosages used in conjunction with the chimeric antibody relative to the murine antibody. This scenario allows for a decrease in bone marrow toxicity to an acceptable level, while maintaining therapeutic utility.

**Page 26, lines 15-26,** replace the paragraph below "i. MX-DTPA" with the following:

Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triamminepentaacetic acid ("carbon-14 labeled MX-DTPA") was used as a chelating agent for conjugation of radiolabel to 2B8. Manipulations of MX-DTPA were conducted to maintain metal-free conditions, *ie* metal-free reagents were utilized and, when possible, polypropylene plastic containers (flasks, beakers, graduated cylinders, pipette tips) washed with ~~Alconox~~ ALCONOX detergent (Alconox, Inc.) and rinsed with ~~Milli-Q~~ MILLI-Q purified water (Millipore, Inc.), were similarly utilized. MX-DTPA was obtained as a dry solid from Dr. Otto Gansow (National Institute of Health, Bethesda, Md.) and stored desiccated at 4°C (protected from light), with stock solutions being prepared in ~~Milli-Q~~ MILLI-Q water at a concentration of 2-5 mM, with storage at -70°C. MX-DTPA was also obtained from Coulter Immunology (Hialeah, Fla.) as the disodium salt in water and stored at -70° C.

**Substitute the replacement abstract on the following page** for the abstract filed with the application.

**Substitute the replacement sequence listing** for the current sequence listing.